Current investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are showing significant results in treating obesity and diabetes non-insulin-dependent diabetes. Initial data suggest a distinct https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/